

**Sunday, 29 May 2016**

---

**08:00-17:00 Registration**

---

---

**08:45-09:00 S1: Opening Ceremony** **Hall A**  
Chairs: **Stefan Agewall**, Norway; **Basil Lewis**, Israel

---

**Introductions:** Basil Lewis, Chairman-Elect, ESC WG on Cardiovascular Pharmacotherapy

**Greetings:**

Stefan Agewall, Chairman, ESC WG on Cardiovascular Pharmacotherapy

Dan Atar, Vice-President, European Society of Cardiology

Michael Glikson, President, Israel Heart Society

Michael Shechter, Chairman, Israel Heart Society WG on Cardiovascular Pharmacotherapy

---

**09:00-10:30 S2: New Challenges in Treatment of Hypertension** **Hall A**  
Chairs: **Stefan Agewall**, Norway; **Antonio Coca**, Spain

---

*Joint Session with Council on Hypertension*

09:00 **Best Therapy for Resistant Hypertension: The Pathway Study**  
Antonio Coca, Dept. of Hypertension & Vascular Risk Unit Hospital Clinic (IDIBAPS). University of Barcelona, Spain

09:20 **Comparing the Results of Pharmacotherapy vs. Device Intervention in Resistant Hypertension**  
Sverre Kjeldsen, Dept. of Cardiology, University of Oslo Ullevaal Hospital, Norway

09:40 **When to Start the Treatment of Arterial Hypertension?**  
Juan Tamargo, Spain

10:00 **TBA**  
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel

10:20 Q & A

---

**10:30-11:00 Coffee Break, Networking, Exhibition Visit and Posters Viewing**

---

---

**11:00-13:00 S3: Hot Topics in Heart Failure** **Hall A**  
Chairs: **Keld Per Kjeldsen**, Denmark

---

11:00 **Debate on: Entresto should be First Line Therapy in HFrEF**  
Pro: Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia  
Con: Giuseppe M.C. Rosano, Cardiovascular Clinical Academic Group, St George's Hospital NHS Trust Medical School, London, UK

11:30 **Debate on: SGLT2 Inhibitors for Type 2 Diabetes Mellitus: Do we need HF Specific Trials?**  
Pro: TBA  
Con: Claudio Ceconi

12:00 **Debate on: Beta-Blockers and Digoxin can benefit HFrEF Patients with Atrial Fibrillation**  
Pro: Dipak Kotecha, Institute of Cardiovascular Science, University of Birmingham, Medical School, Birmingham, UK  
Con: Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia

12:30 **Obesity in Heart Failure: Update 2016**  
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany

<b>13:00-14:00</b>	<b>S4: Satellite: Novartis on Heart Failure</b> Chairs: <b>Felipe Martinez</b> , Argentina; <b>Jean-Marc Weinsten</b> , Israel	<b>Hall A</b>
13:00	Role of Nephilysin Inhibitors in CV Disease: What can we Learn from PARADIGM? <u>Petar Seferovic</u> , Dept. of Cardiology, Belgrade School of Medicine, Serbia	
13:30	Heart Failure Guidelines 2016: What is New? <u>Stefan Anker</u> , Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany	
13:45	Panel Discussion: Which Patients and when to use Sacubitril/Valsartan (Entresto)? <u>Offer Amir</u> , <u>Tuvia Ben Gal</u> , <u>Israel Gotsman</u> , <u>Andre Keren</u> , <u>Avi Shotan</u> , Israel	
<b>13:00-14:00</b>	<b>Lunch S14: Satellite: AstraZeneca on DAPT</b> Chairs:	<b>Hall B</b>
<b>14:00-15:00</b>	<b>S5: Satellite: Boehringer on Diabetes Mellitus</b> Chairs: <b>Avi Karasik</b> , Israel	<b>Hall A</b>
<b>15:00-16:00</b>	<b>S6: Myocardial and Pericardial Disease</b> Chairs: <b>Shemy Carasso</b> , Israel; <b>Daniel Monakier</b> , Israel	<b>Hall A</b>
	<i>Joint Session with ESC Working Group on Myocardial and Pericardial Disease</i>	
15:00	<b>TBA</b>	
15:20	<b>TBA</b>	
15:40	<b>TBA</b>	
<b>16:00-16:30</b>	<b>Coffee Break, Networking, Exhibition Visit and Posters Viewing</b>	
<b>16:30-18:00</b>	<b>S7: New Directions in Heart Failure</b> Chairs: <b>Stefan Agewall</b> , Norway; <b>Stefan Anker</b> , Germany	<b>Hall A</b>
	<i>Joint Session with Heart Failure Association of the ESC</i>	
16:30	<b>Potassium Lowering Drugs</b> <u>Mitja Lainscak</u> , Dept. of Cardiology, General Hospital Celje, Slovenia	
16:50	<b>Iron Therapy</b> <u>Stefan Anker</u> , Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany	
17:10	<b>New Therapies for Acute Decompensated Heart Failure</b> TBA	
17:40	<b>Non-Pharmacologic Therapies for Advanced Heart Failure</b> <u>Offer Amir</u> , Dept. of Cardiology, Baruch Padeh Medical Center, Poriya, Israel	
18:00-19:00	<i>Get Together Cocktails</i>	

<b>08:00</b>	<b>Registration</b>	
<b>08:30-10:00</b>	<b>S8: Gender Differences in Cardiovascular Pharmacology</b> Chairs:	<b>Hall A</b>
08:30	<b>Gender Differences in Pharmacology</b> <u>Thomas Walther</u> , Dept. of Pharmacology & Therapeutics, University College Cork, Ireland	
08:50	<b>Gender Differences in Clinical Trials</b> <u>Juan Tamargo</u> , Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain	
09:10	<b>Gender Differences in Cardiovascular Side Effects</b> <u>Giuseppe Rosano</u> , Cardiovascular Clinical Academic Group, St George's Hospital NHS Trust Medical School, London, UK	
09:30	<b>Gender Differences in Treatment Delivery</b> <u>Avital Porter</u> , ICCU and The Women's Cardiac Health Clinic, Rabin Medical Center-Beilinson, and the Sackler Faculty of Medicine, Tel Aviv, Israel	
09:50	Q & A	
<b>10:00-10:30</b>	<b>Coffee Break, Networking, Exhibition Visit and Posters Viewing</b>	
<b>10:30-11:30</b>	<b>S9: Individualizing Antithrombotic Therapy</b> Chairs: <b>L. Buryachkovskaya</b> , Russia <b>N. Lomakin</b> , Russia	<b>Hall A</b>
	<i>Russian Scientific Inflammation Society, Central Clinical Hospital of the Presidential Department of Russian Federation</i>	
10:30	<b>Laboratory Monitoring of Antiplatelet Therapy</b> <u>Nikita Lomakin</u> , Russia	
10:50	<b>Genetic Aspects of Antithrombotic Therapy</b> <u>Alexey Meshkov</u> , Russia	
11:10	<b>Role of Local Inflammation in the Development of Instent Restenosis</b> <u>Zufar Gabbasov</u> , Russia	
<b>11:30-13:00</b>	<b>S10: Critical Issues in Antithrombotic Therapy: 2016 Update</b> Chairs: <b>Stefan Agewall</b> , Norway; <b>Joao Morais</b> , Portugal	<b>Hall A</b>
	<i>Joint Session with Working Group on Thrombosis</i>	
11:30	<b>DAPT Duration after Stenting in Stable CAD</b> <u>Sven Wassmann</u> , Dept. of Cardiology, Isar Heart Center, Isar Klinikum, Munich, Germany	
11:45	<b>DAPT Duration after Myocardial Infarction</b> <u>Sigrun Halvorsen</u> , Dept. of Cardiology, Oslo University Hospital, Ullevaal, Norway	
12:00	<b>Antithrombotic Therapy in Patients with AF and ACS</b> <u>Dan Atar</u> , Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway	
12:15	<b>Should NOACs Totally replace VKA, Aspirin for Stroke Prevention in AF?</b> <u>Joao Morais</u> , Div. of Cardiology, Santo Andre's Hospital, Leiria, Portugal	
12:30	<b>Reversal Strategies for Non-VK Oral Anticoagulants</b> <u>Alexander Niessner</u> , Dept. of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria	
12:45	Q & A	
<b>13:00-14:00</b>	<b>Lunch S11: Satellite: Pfizer on NOACs</b> Chairs: <b>Yoseph Rozenman</b> , Israel	<b>Hall A</b>

<b>13:00-14:00</b>	<b>Lunch S15: Satellite: Amgen on Lipid Lowering</b> Chairs:	<b>Hall B</b>
<b>14:00-15:30</b>	<b>S12: Intersociety Opinion: New Drugs and Therapies</b> Chairs: <b>Stefan Agewall</b> , Norway; <b>Felipe Martinez</b> , Argentina	<b>Hall A</b>

*Joint Session with International Society of Cardiovascular Pharmacotherapy*

14:00	<b>New Anti-Arrhythmics</b> <u>George Dan</u> , University of Medicine "Carol Davila", Bucharest, Romania
14:20	<b>New Anti-Thrombotics</b> <u>Antoni Martínez Rubio</u> , Dept. of Cardiolofy, Hospital de Sabadell, Barcelona, Spain
14:40	<b>New Drugs for Angina and CAD</b> <u>Juan Tamargo</u> , Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain
15:00	<b>New Drugs for Heart Failure</b> <u>Felipe A. Martinez</u> , Cordoba National University. Argentina
15:20	Conclusion